We are excited to be presenting the free online 15th Vaccine Congress: Mid-Year Review, which will take place on 19 April 2021. We will hear from leading experts on the development and implementation of the newest Covid-19 vaccines.
Speakers will each give a presentation followed by a live panel discussion where you will be able to pose your questions directly to them.
By attending you will gain a unique insight into the latest discoveries as well as a highly valuable opportunity to connect with world experts in the global vaccine community.
President, Research & Development, Novavax Inc, USA
Dr. Glenn is the president of research and development and leads the discovery, clinical, and regulatory teams. He has spent 28 years in the design and development of vaccines, vaccine delivery, and adjuvants.
View full bio
He has led the development of products from concept to late-stage clinical development, including COVID-19, RSV, recombinant adjuvanted seasonal and pandemic influenza vaccines, Ebola, and an Enterotoxigenic E. coli vaccine patch, and participated in other programs including the development of a malaria vaccine. He is the cofounder of IOMAI and provided the scientific and technical leadership that led to the acquisition by Intercell in 2008. He worked for Intercell from 2008 to 2010. He is the coauthor of more than 100 peer-reviewed scientific publications. Dr. Glenn was board certified and practiced pediatrics prior to completing a Medical Research Fellowship at the Walter Reed Army Institute of Research where he continued as a clinician-researcher prior to entering into commercial vaccine development in 1997. Dr. Glenn received a bachelor of arts degree in biology and chemistry from Whitman College in Washington and a doctor of medicine degree from Oral Roberts University School of Medicine in Oklahoma.
Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson's Janssen Vaccines & Prevention, The Netherlands
Hanneke Schuitemaker, Ph.D., is the Head of Viral Vaccine Discovery and Translational Medicine and Disease Area Stronghold Leader for Viral Vaccines at Janssen Vaccines & Prevention B.V. She has been in these roles since 2010 and oversees the early development of Janssen’s viral vaccine programs including investigational vaccine candidates for HIV, respiratory syncytial virus (RSV), Ebola, Zika, and COVID-19. In addition, she is a Professor of Virology at the Amsterdam University Medical Center.
View full bio
Hanneke Schuitemaker is a medical biologist by training, received her Ph.D. in Medicine in 1992 at the University of Amsterdam and worked for more than 20 years on HIV-1 pathogenesis, first at Sanquin (1989-2007), the blood supply foundation in the Netherlands, where she was the Chair of the department of Clinical Viro-Immunology (1998-2007), and then at the Amsterdam University Medical Center (2008-2010), where she was the Chair of the Department of Experimental Immunology. From mid-2003 to mid-2004, she worked as a visiting scientist at The Scripps Research Institute in La Jolla, California. She successfully trained more than 30 Ph.D. students and co-authored more than 300 peer-reviewed scientific articles.
Brian J. Ward
Medical Officer, Medicago, USA
Dr. Brian Ward is passionate about science and innovation. He has active research interests in RNA viruses, vaccine development and international health supported by Canadian and international funding agencies as well as private foundations and industry.
View full bio
He is a Professor of Medicine and Microbiology at McGill University and serves on several national and international advisory committees in the areas of vaccine use, vaccine safety and international health.
Moderator and Conference Chair
Gregory A. Poland
Editor in Chief, Vaccine and Mayo Clinic, USA
The Vaccine Research Group uses immunological testing, including serology, cell-mediated immunity, cell culture and cytokine assays; polymerase chain reaction (PCR) techniques and HLA typing for immunogenetic studies; and high-throughput assays, such as next-generation sequencing, transcriptomics, mass spectrometry and proteomic analysis.
View full bio
Dr. Poland's research has been continuously funded by the National Institutes of Health since 1991.
What is "vaccinomics?"
Coined by Dr. Poland and his team in 2007, the term "vaccinomics" refers to the development of personalized vaccines based on the increased understanding of immune response phenotype-genotype information. Through research, Dr. Poland and his team aim to explain how vaccine-induced immune responses and vaccine-related adverse events may be genetically determined — and therefore predictable.
Monday, 19 April 2021
|13:30-13:45 GMT||Introduction, Gregory A. Poland, Editor in Chief, Vaccine and Mayo Clinic, USA|
|13:45-14:45 GMT||Hanneke Schuitemaker, Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson's Janssen Vaccines & Prevention, The Netherlands|
|14:15-14:45 GMT||Brian J. Ward, Medical Officer, Medicago, USA|
|14:45-15:15 GMT||Gregory Glenn, President, Research & Development, Novavax Inc, USA|
|15:15-16:00 GMT||Live panel discussion with Q&A with all speakers|